Replies to post #172112 on Cytodyn Inc (CYDY)

[misiu143]

The problem often is..not enough of efficacy and serious side effects...

So here with tofacitinib study .....study randomized 1:1..double-blind ,placebo control..

" In 20 patients ( 14.1%) in the study drug group , and 17 ( 12.0) in the placebo group experience serious adverse events..( SAEs)
included ...

--deep vein thrombosis ,
--acute myocardial infarction ,
--ventricular tachycardia ,

Now we may all read SAEs with leronlimab CD12 study , or ANY leronlimab study , ..well , it is impressive for leronlimab ...not like tofacitinib ..
much better with efficacy and any side effects..

all IMO.

[theswordman]

"trials move forward soon in Brazil"--so as far as this pfizer trial--it was 1st posted JUL 2020--PH2--260 patients

it is end JUN 2021

there was nothing "soon" in their trial